These three reports are based on a survey conducted by Baker McKenzie in collaboration with Informa Pharma Intelligence. The series features insights from over 250 life sciences executives in the Americas, Europe and Asia Pacific. Explore how pharmaceutical, biotech, medical devices and medtech companies plan to evolve their business models, shaping the future of the life sciences ecosystem.
Report 2: Funding Growth and the Future of Life Sciences
How do life sciences companies intend to leverage new and existing sources of growth? Explore the trajectory of life sciences transactions in our latest report that focuses on:
- The enduring robust appetite for M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements
- A rising focus on sustainability goals aligned with pursuing deals linked to corporate power purchase agreements (PPAs) and green financing
- Continued VC investment and increasing appetitive from private equity sponsors in pre-revenue stages
- Regional divergences and subsector trends
Other Reports in the Series
Report 1: How Digital Transformation and Data Are Shaping Business Models
As digital transformation reshapes business models with different emphases across regions, digitally enabled strategies are helping companies transition from product-only offerings to product-service hybrids, orient to patient mapping, pre-diagnostics solutions and enhancing treatment administration. These intertwined value chains are increasingly shaping the life sciences industry of the future.
Upcoming Report 3: Shaping Growth — Collaboration, Supply & Manufacturing
(Launching March 2022)
As life sciences companies respond to market demand, shifting patient needs and cost pressures, we asked respondents what is influencing their decisions on where, how and what to pursue in terms of development of therapies, modalities and product-service hybrids.
Sign up to receive a copy of our upcoming reports straight to your inbox.